Business Wire Feed
Precisio Biotix Therapeutics, Inc. (Precisio) Announces the Use of Its ClyO (Staph Lysin) to Treat a Multi Drug-Resistant Prosthetic Joint Infection (PJI) Under an Expanded Access Chronic Care Management Protocol
Lysins are a promising new family of enzyme-based antimicrobials which offer unique properties compared to antibioticsOrthopedic infections, especially those caused by methicillin-resistant Staph bacteria, are increasingly problematic because of biofilms and antibiotic resistance, requiring drastic more...
Mirion Supports Advanced Reactor Criticality Milestones Through U.S. DOE Reactor Pilot Program
Mirion Technologies and Paragon Energy Solutions Provide Radiation Monitoring and Nuclear Safety Systems for Advanced Reactor DemonstrationsATLANTA--(BUSINESS WIRE)--Mirion, a global leader in radiation safety, science, and medicine, announced today that its Mirion Technologies and Paragon more...
Qtis.ai Launches AI-Native Clinical Research Division, Enters Fast-Growing $7.4 Billion CTMS Market
New platform aims to modernize decades-old clinical research infrastructure with purpose-built AI architectureCUPERTINO, Calif.--(BUSINESS WIRE)--#CTMS--Qtis.ai, an applied artificial intelligence company focused on healthcare, medical research, and aesthetics, today announced the launch of its Clinical Research more...
ZETA TMS Robotic System Receives FDA 510(k) Clearance
BOSTON--(BUSINESS WIRE)--ZETA SURGICAL today announced that its Zeta TMS Robotic System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The device is classified as a Class II stereotaxic instrument under 21 more...
Banyan Software Acquires HMM
Moers-based eHealth platform joins Banyan to accelerate its next phase of growthMUNICH--(BUSINESS WIRE)--#B2BeHealthPlatform--Banyan Software, a Canadian-based acquirer and long-term operator of successful software businesses headquartered in Toronto, is pleased to announce the acquisition of HMM more...
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
Phase 2 study did not meet its primary endpoint. Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of vision-threatening disease with a primary more...
Acadia Healthcare Announces Date for Second Quarter 2026 Earnings Release
FRANKLIN, Tenn.--(BUSINESS WIRE)--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2026 results on Tuesday, July 28, 2026, after the close of the market. Acadia will host a conference more...
Baxter to Host Second-Quarter 2026 Financial Results Conference Call for Investors
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its second-quarter 2026 financial results on Thursday, July 30, 2026, at 7:30 a.m. Central Time. To participate more...
Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter more...
Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. Company management more...
GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its second quarter 2026 financial results after U.S. markets more...
Concentra to Announce Second Quarter 2026 Results on Thursday, August 6, 2026
DALLAS--(BUSINESS WIRE)--Concentra® Group Holdings Parent, Inc. (“Concentra”) (NYSE: CON) will release the financial results for its second quarter ended June 30, 2026, on Thursday, August 6, 2026, after the market closes. Concentra will host a more...
Reinsurance Group of America Announces Second Quarter Earnings Release Date, Webcast
ST. LOUIS--(BUSINESS WIRE)--Reinsurance Group of America, Incorporated (NYSE:RGA) plans to release second quarter earnings on Thursday, August 6, at approximately 4:15 p.m. Eastern Time. The release will be issued via newswire and will also be more...
Anthem Establishes Coverage of C2N Diagnostics’ PrecivityAD2® Blood Test for Alzheimer’s Disease Evaluation
Medical policy marks a key commercial milestone as one of the nation's largest insurers recognizes the clinical importance of Alzheimer's blood biomarker testingST. LOUIS--(BUSINESS WIRE)--#Alzheimers--C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision more...
Haypp Group Issues Statement on FDA’s Modified Risk Orders for Specific ZYN Products
Online retailer says FDA action underscores the importance of adult-only access and product-specific regulatory standardsWASHINGTON--(BUSINESS WIRE)--Haypp Group, parent company of Nicokick.com and Northerner.com, today issued the following statement in response to the U.S. Food and Drug Administration’s (FDA) more...
Anthem Blue Cross and Blue Shield in Virginia and VCU Health Announce Multi-Year Agreement to Advance Affordability and Innovation
RICHMOND, Va.--(BUSINESS WIRE)--Anthem Blue Cross and Blue Shield in Virginia and VCU Health today announced a new multi-year agreement that reinforces their longstanding relationship and shared commitment to improving health outcomes across the Commonwealth. The more...
LEO Pharma Announces Key Results of Phase 2 TRAPEDS-1 Trial Evaluating Pharmacokinetics and Safety of Tralokinumab in Children With Moderate-to-Severe Atopic Dermatitis
TRAPEDS-1 is a Phase 2 trial evaluating the pharmacokinetics and long-term safety of tralokinumab in children aged 6 to 11 years with moderate-to-severe atopic dermatitis.1 The pharmacokinetic profile was as expected and consistent with what more...
OpenEvidence and NewYork-Presbyterian, Columbia University and Weill Cornell Medicine Expand Clinical AI Tools Across New York City and Westchester
MIAMI & NEW YORK--(BUSINESS WIRE)--#MedicalAI--OpenEvidence, a medical AI and clinical decision support tool for U.S. clinicians, today announced a collaboration with NewYork-Presbyterian and its affiliated medical schools, Columbia University Vagelos College of Physicians and Surgeons more...
Olio and Cantex Raise the Standard for Skilled Nursing Care Transitions Across Texas
Cantex Continuing Care Network is deploying Olio across its skilled nursing facilities to build a transitions-of-care discipline ahead of most operators and bring real visibility to patient progress in home health and hospice.INDIANAPOLIS--(BUSINESS WIRE)--#CareCoordination--Olio today more...
Independent Recognition Reinforces Auragens’ Position as a Global Leader in Regenerative Medicine
First organization to earn Life Sciences Review's "Stem Cell Treatment Center of the Year" award for two consecutive years, validating its integrated scientific, manufacturing, and clinical platform.LAS VEGAS & PANAMA CITY, Panama--(BUSINESS WIRE)--#AABB--Auragens today announced more...
IKS Health Completes Acquisition of TruBridge
Combined organization poised to become the technology backbone of rural and community careDALLAS & MOBILE, Ala.--(BUSINESS WIRE)--IKS Health, a global leader in care enablement solutions across the patient journey, today announced the successful completion of more...
As 340B Grows More Complex, Covered Entities Need Clearer Visibility Across Vendor Relationships, Contract Pharmacy Arrangements, Manufacturer Restrictions, Referral Activity, and Emerging IRA/MFP Requirements
WILLIAMSON, W.Va.--(BUSINESS WIRE)--Halo340B today called on Federally Qualified Health Centers and other 340B covered entities to take a more strategic and mission-driven approach to understanding their 340B gross-to-net performance. For covered entities, gross-to-net should be more...
Messagepoint MARCIEAssure™ Named ”AI-based Healthcare Solution of the Year” in 2026 AI Breakthrough Awards Program
Ninth Annual Program Honors the AI Innovators Shaping the Next Era of Global InnovationTORONTO--(BUSINESS WIRE)--Messagepoint, a leading customer communications management (CCM) solutions provider, today announced that MARCIEAssure™ has been awarded “AI-based Healthcare Solution of the more...
The California Department of State Hospitals Selects Netsmart as Its Modernized, Data-Driven Technology Platform
Collaboration builds on Netsmart leadership in the public sector, expanding relationships across California while advancing connected, data-driven care for behavioral healthcareOVERLAND PARK, Kan.--(BUSINESS WIRE)--#ArtificialIntelligence--The California Department of State Hospitals (DSH) has selected the Netsmart CareFabric® more...
American Women Are Being Let Down: Only 1-In-3 Voters Say the U.S. Health Care System Is Meeting Women’s Needs
New National Survey Exposes a Widening Gap Between the Care Women Need and the Care They ReceiveWASHINGTON--(BUSINESS WIRE)--A sweeping new national voter survey paints a troubling picture of women’s health care in America today. Despite more...